Skip to main content

$1.23 -0.02 (-1.21%)

High

$1.29

Low

$1.18

Trades

155

Turnover

$303,224

Volume

249,053
30 June 2023 at 4:10pm
Register to track RAC and receive email alerts.
Subject
RAC Ann: Notification of cessation of securities - RAC

RAC Ann: Proposed issue of securities - RAC

RAC Ann: Initial Director's Interest Notice

RAC Ann: Final Director's Interest Notice

RAC Ann: Race Board Changes

RAC Ann: Update - Notification of buy-back - RAC

RAC Ann: Race Completes On-Market Buy-Back Program

RAC Ann: Letter to Shareholders

RAC Ann: Ceasing to be a substantial holder

RAC Ann: Cleansing Notice

RAC Ann: Application for quotation of securities - RAC

RAC Ann: Race appoints Dr Michelle Rashford Chief Medical Officer

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: Race continues Board renewal - appoints new Chair

RAC Ann: Race releases complete cardio-protection data & video

RAC Ann: Race releases cardioprotection market potential data

RAC Ann: Race Receives $1.48m R&D Tax Refund for Financial Year 2022

RAC Ann: Final Director's Interest Notice - Dr Daniel Tillett

RAC Ann: Race Leadership Changes

RAC Ann: Trading Halt

RAC Ann: Pause in Trading

RAC Ann: Race Executes Contracts to Commence Breast Cancer Trial

RAC Ann: Replacement Appendix 3Y - Damian Clarke Bruce

RAC Ann: Appendix 3Y x 3

RAC Ann: Notification regarding unquoted securities - RAC

RAC Ann: New Collaboration to Understand Zantrene Cardioprotection

RAC Ann: Appendix 4D & Half-Year Financial Statements

RAC Ann: Results of Meeting

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Cleansing Notice

RAC Ann: Application for quotation of securities - RAC

RAC Ann: Replacement Appendix 3X - Damian Clarke-Bruce

RAC Ann: Race Receives Cardioprotection Ethics Trial Approval

RAC Ann: Appendix 3X - Damian Clarke-Bruce

RAC Ann: Quarterly Activity Report & Appendix 4C

RAC Ann: Letter to Shareholders, Notice of Meeting & Proxy Form

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: December 2022 Preclinical & Clinical Programs Update

RAC Ann: Race supports Study of Extramedullary AML

RAC Ann: Appendix 3Y - Dr Daniel Tillett

RAC Ann: Proposed issue of securities - RAC

RAC Ann: Race Appoints Damian Clarke-Bruce as CEO & Managing Director

RAC Ann: Ethics submission to commence cardioprotection trial

RAC Ann: Appendix 3X - Danny Sharp

RAC Ann: Proposed issue of securities - RAC

RAC Ann: Danny Sharp appointed Independent Non-Executive Director

RAC Ann: Constitution

RAC Ann: Results of Annual General Meeting

RAC Ann: Race 2022 AGM Presentations

RAC Ann: Positive Pre-IND Guidance from FDA on Zantrene

Register to track RAC and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
TLX